In 2018, medical cannabis products were legalized for the first time in the United Kingdom. Subsequent to this legalization, the country's medical cannabis market is forecasted to increase in size massively. In 2023, the of medicinal cannabis market in the UK stood at *** million U.S. dollars, and by 2027 it is projected to exceed *** million U.S dollars.

The number of medical cannabis patients in the U.S. according to estimates mostly from year-end 2024 was highest in the State of Florida. Florida had around *** thousand medical cannabis patients at that time. In that same year, Oklahoma had the highest percentage of medical cannabis patients. Medical marijuana There may be many positive effects of medical cannabis, including to patient health and to the economy. However, medical cannabis market forecasts in the U.S. for the coming years have been revised down. From a medical point of view, the most commonly cited benefits of the drug were pain reduction and sleep. There are currently numerous research projects underway in the U.S. to determine the medical benefits and therapeutic uses of marijuana products, as well as the potential impact of marijuana legalization on the U.S. economy. Public opinionPublic opinion on the effects of marijuana and its ability to be used in patient care vary. However, it is clear that many U.S. adults support the legalization of marijuana in some form. A recent study indicated that the support for marijuana legalization has been increasing in recent history. Another study has shown that an overwhelming majority of participants felt that cannabis has valid medical uses. Despite current efforts at legalization and research underway, marijuana with over *** percent of THC – for any use – is considered illegal under federal U.S. law.

This data set contains preliminary weekly retail sales data for cannabis and cannabis products in both the adult-use cannabis and medical marijuana markets. The data reported is compiled at specific points in time and only captures data current at the time the report is generated. The weekly data set captures retail cannabis sales from Sunday through Saturday of the week. Weeks spanning across two different months only include days within the same month. The first and last week of each month may show lower sales as they may not be made up of a full week (7 days). Data values may be updated and change over time as updates occur. Accordingly, weekly reported data may not exactly match annually reported data.

Data source: Cannabis Retail Sales by Week Ending

Image Source: Unsplash

This dataset contains the Medical Marijuana Registry Program Update by County as of January 31, 2014.

This statistic shows medical cannabis sales worldwide from 2023 to 2027. Global sales stood at nearly ** billion U.S. dollars in 2023. By 2027, it is projected that the number will increase up to approximately ** billion dollars.

A medical cannabis retailer is a licensed establishment that may possess and dispense medical cannabis and paraphernalia to licensed patients and caregivers. The medical cannabis sold by a retailer is provided to them by a DC-licensed and located medical cannabis cultivator.

This dataset tracks the updates made on the dataset "Medical Marijuana Statistics - County Information" as a repository for previous versions of the data and metadata.

Please note that this list does not include all certifying healthcare providers. The list only includes those providers who have consented to be publicly listed. Please click the ‘Data’ tab to view the list of consenting providers. You can search the data by any field.

This dataset tracks the updates made on the dataset "Medical Marijuana Statistics - County Information" as a repository for previous versions of the data and metadata.

In 2018 medical cannabis products were legalized for the first time in the United Kingdom, since then the number of patients using these products is predicted to increase significantly. At the end of 2019, there were less than *** active medical cannabis users, by 2024 the number of users is expected to rise to approximately ***** thousand.

These are the source data used to create Figures 2 - 7 of the forthcoming publication: Shim MS, Nguyen HV, Grootendorst P. Lessons from 20 years of medical cannabis use in Canada. PLOS One, forthcoming. Figures 8 and 9 of the paper rely on public use versions of the Statistics Canada and Health Canada survey data which were obtained from ODESI. Licensing restrictions prevent reposting the source data.

This data represents the number of individuals registered in the Department of Consumer Protection's Medical Marijuana Program by registration type on the last day of the month.

The Europe medical cannabis market size reached USD 2,586.1 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 12,652.9 Million by 2033, exhibiting a growth rate (CAGR) of 18.33% during 2025-2033. The market is poised for significant growth with increase in legalization and expanding therapeutic applications of the product and the rising patient demand for cannabis. Technological advancements in cultivation and extraction technologies, strategic partnerships and growing investment in research and development (R&D) are also contributing positively to the market growth.

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the regional and country levels for 2025-2033. Our report has categorized the market based on species, derivative, application, end use and route of administration.

Listing of all the medical marijuana and cannabis products registered with the State Dept. of Consumer Protection

This data set contains preliminary monthly sales data for the average price per gram of usable cannabis in both the adult-use cannabis and medical marijuana markets. For the purposes of this dataset, "usable cannabis" includes raw flower in whole, ground, or pre-rolled form, without additional extracted materials. The data reported is compiled at specific points in time and only captures data current at the time the report is generated. Data values may be updated and change over time as updates occur.

In 2023, the medical cannabis market in Europe was valued at approximately 745 million U.S. dollars. In the following years, as more European countries will introduce legalization, the market is expected to increase significantly. Forecasts show that by 2027, the market could reach around 2.2 billion U.S. dollars.

The Medical Cannabis market has emerged as a significant segment within the broader healthcare industry, gaining momentum due to increasing acceptance of cannabis for therapeutic applications. Originally stigmatized, medical cannabis is now recognized for its potential in alleviating chronic pain, managing anxiety,

This data set contains preliminary retail sales data for cannabis and cannabis products by product type in the adult-use cannabis and medical marijuana markets based on total sales data. The data reported is compiled at specific points in time and only captures data current at the time the report is generated. The monthly data set captures retail cannabis sales from the first through the last day of the month. Data values may be updated and change over time as updates occur. Accordingly, monthly reported data may not exactly match annually reported data.

BackgroundThe trends of recreational use of cannabis and the use of cannabis for medical indications (i.e., “medical cannabis”) have grown in recent years. Despite that, there is still limited scientific evidence to guide clinical decision-making, and the strength of evidence for the medical use of cannabis is currently considered to be low. In contrast, there is growing evidence of negative health outcomes related to the use of cannabis. In this rapidly shifting landscape, the role of physician attitudes regarding the therapeutic value of cannabis has become essential. This study aimed to characterize knowledge/experience, attitudes, and potential predictors of clinical practice regarding medical cannabis.MethodsWe conducted a cross-sectional survey of physicians from 17 countries between 2016 and 2018. The survey consisted of questions designed to explore physician knowledge, attitude, and practices regarding the use of medical cannabis. Descriptive statistics were used to examine willingness to recommend medical cannabis for medical and psychiatric indications, followed by regression analysis to identify the predictors of physician willingness to recommend medical cannabis.ResultsA total of 323 physicians responded to the survey, among which 53% were women. The mean age was 35.4 ± 9.5 years, with 10.04 ± 8.6 years of clinical experience. Clinical experience with medical cannabis was overall limited (51.4% noted never having recommended medical cannabis and 33% noted inadequate knowledge regarding medical cannabis). The majority of respondents (84%) recognized the risk of psychosis with cannabis use, while only 23% correctly identified the risk of addiction with daily cannabis use. Overall, willingness to recommend medical cannabis was the highest for chemotherapy-induced nausea (67%), refractory chronic neuropathic pain (52%), and spasticity in amyotrophic lateral sclerosis (ALS; 51%).ConclusionThis international study examining physician knowledge, attitudes, and practices related to medical cannabis revealed that there are significant gaps in domain-specific knowledge related to medical cannabis. There is a wide variability in willingness to recommend medical cannabis, which is not consistent with the current strength of evidence. This study thus highlights the need for greater education related to domain-specific knowledge about medical cannabis.

Financial overview and grant giving statistics of Maryland Wholesale Medical Cannabis Trade Association